MicroRNAs-Mediators of myometrial contractility during pregnancy and labour

Nora E. Renthal, Koriand'R C. Williams, Carole R. Mendelson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The maintenance of myometrial quiescence and initiation of contractility, which lead to parturition at term and preterm, involve a shifting equilibrium between anti-inflammatory and proinflammatory signalling pathways. Progesterone (P4), acting through the progesterone receptor (PR), has an essential and multifaceted role in the maintenance of myometrial quiescence. This effect of P4-PR signalling is mediated, in part, by its anti-inflammatory actions and capacity to repress the expression of genes that encode proinflammatory cytokines, such as IL-1 and IL-6, and contraction-associated proteins, such as OXTR, GJA1 and PTGS2. By contrast, increased expression of genes that ultimately lead to parturition is mediated by enhanced inflammatory and estradiol-17β (E2) and estrogen receptor α signalling, which reduce PR function, thus further intensifying the inflammatory response. To obtain a more complete understanding of the molecular events that underlie the transition of the pregnant myometrium from a refractory to a contractile state, the roles of microRNAs, their targets, and their transcriptional and hormonal regulation have been investigated. This article reviews the actions of the miR-200 family and their P4-regulated targets-the transcription factors ZEB1, ZEB2 and STAT5B-in the pregnant myometrium, as well as the role of miR-199a-3p and miR-214 and their mutual target PTGS2. The central role of ZEB1 as the mediator of the opposing actions of P4 and E2 on myometrial contractility will be highlighted.

Original languageEnglish (US)
Pages (from-to)391-401
Number of pages11
JournalNature Reviews Endocrinology
Volume9
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Progesterone Receptors
MicroRNAs
Myometrium
Cyclooxygenase 2
Pregnancy
Anti-Inflammatory Agents
Maintenance
Parturition
Gene Expression
Interleukin-1
Estrogen Receptors
Progesterone
Estradiol
Interleukin-6
Transcription Factors
Cytokines
Proteins

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

MicroRNAs-Mediators of myometrial contractility during pregnancy and labour. / Renthal, Nora E.; Williams, Koriand'R C.; Mendelson, Carole R.

In: Nature Reviews Endocrinology, Vol. 9, No. 7, 07.2013, p. 391-401.

Research output: Contribution to journalArticle

Renthal, Nora E. ; Williams, Koriand'R C. ; Mendelson, Carole R. / MicroRNAs-Mediators of myometrial contractility during pregnancy and labour. In: Nature Reviews Endocrinology. 2013 ; Vol. 9, No. 7. pp. 391-401.
@article{22c6bc1dc3c9402dbfb8f75e574a3544,
title = "MicroRNAs-Mediators of myometrial contractility during pregnancy and labour",
abstract = "The maintenance of myometrial quiescence and initiation of contractility, which lead to parturition at term and preterm, involve a shifting equilibrium between anti-inflammatory and proinflammatory signalling pathways. Progesterone (P4), acting through the progesterone receptor (PR), has an essential and multifaceted role in the maintenance of myometrial quiescence. This effect of P4-PR signalling is mediated, in part, by its anti-inflammatory actions and capacity to repress the expression of genes that encode proinflammatory cytokines, such as IL-1 and IL-6, and contraction-associated proteins, such as OXTR, GJA1 and PTGS2. By contrast, increased expression of genes that ultimately lead to parturition is mediated by enhanced inflammatory and estradiol-17β (E2) and estrogen receptor α signalling, which reduce PR function, thus further intensifying the inflammatory response. To obtain a more complete understanding of the molecular events that underlie the transition of the pregnant myometrium from a refractory to a contractile state, the roles of microRNAs, their targets, and their transcriptional and hormonal regulation have been investigated. This article reviews the actions of the miR-200 family and their P4-regulated targets-the transcription factors ZEB1, ZEB2 and STAT5B-in the pregnant myometrium, as well as the role of miR-199a-3p and miR-214 and their mutual target PTGS2. The central role of ZEB1 as the mediator of the opposing actions of P4 and E2 on myometrial contractility will be highlighted.",
author = "Renthal, {Nora E.} and Williams, {Koriand'R C.} and Mendelson, {Carole R.}",
year = "2013",
month = "7",
doi = "10.1038/nrendo.2013.96",
language = "English (US)",
volume = "9",
pages = "391--401",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - MicroRNAs-Mediators of myometrial contractility during pregnancy and labour

AU - Renthal, Nora E.

AU - Williams, Koriand'R C.

AU - Mendelson, Carole R.

PY - 2013/7

Y1 - 2013/7

N2 - The maintenance of myometrial quiescence and initiation of contractility, which lead to parturition at term and preterm, involve a shifting equilibrium between anti-inflammatory and proinflammatory signalling pathways. Progesterone (P4), acting through the progesterone receptor (PR), has an essential and multifaceted role in the maintenance of myometrial quiescence. This effect of P4-PR signalling is mediated, in part, by its anti-inflammatory actions and capacity to repress the expression of genes that encode proinflammatory cytokines, such as IL-1 and IL-6, and contraction-associated proteins, such as OXTR, GJA1 and PTGS2. By contrast, increased expression of genes that ultimately lead to parturition is mediated by enhanced inflammatory and estradiol-17β (E2) and estrogen receptor α signalling, which reduce PR function, thus further intensifying the inflammatory response. To obtain a more complete understanding of the molecular events that underlie the transition of the pregnant myometrium from a refractory to a contractile state, the roles of microRNAs, their targets, and their transcriptional and hormonal regulation have been investigated. This article reviews the actions of the miR-200 family and their P4-regulated targets-the transcription factors ZEB1, ZEB2 and STAT5B-in the pregnant myometrium, as well as the role of miR-199a-3p and miR-214 and their mutual target PTGS2. The central role of ZEB1 as the mediator of the opposing actions of P4 and E2 on myometrial contractility will be highlighted.

AB - The maintenance of myometrial quiescence and initiation of contractility, which lead to parturition at term and preterm, involve a shifting equilibrium between anti-inflammatory and proinflammatory signalling pathways. Progesterone (P4), acting through the progesterone receptor (PR), has an essential and multifaceted role in the maintenance of myometrial quiescence. This effect of P4-PR signalling is mediated, in part, by its anti-inflammatory actions and capacity to repress the expression of genes that encode proinflammatory cytokines, such as IL-1 and IL-6, and contraction-associated proteins, such as OXTR, GJA1 and PTGS2. By contrast, increased expression of genes that ultimately lead to parturition is mediated by enhanced inflammatory and estradiol-17β (E2) and estrogen receptor α signalling, which reduce PR function, thus further intensifying the inflammatory response. To obtain a more complete understanding of the molecular events that underlie the transition of the pregnant myometrium from a refractory to a contractile state, the roles of microRNAs, their targets, and their transcriptional and hormonal regulation have been investigated. This article reviews the actions of the miR-200 family and their P4-regulated targets-the transcription factors ZEB1, ZEB2 and STAT5B-in the pregnant myometrium, as well as the role of miR-199a-3p and miR-214 and their mutual target PTGS2. The central role of ZEB1 as the mediator of the opposing actions of P4 and E2 on myometrial contractility will be highlighted.

UR - http://www.scopus.com/inward/record.url?scp=84879417902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879417902&partnerID=8YFLogxK

U2 - 10.1038/nrendo.2013.96

DO - 10.1038/nrendo.2013.96

M3 - Article

C2 - 23669656

AN - SCOPUS:84879417902

VL - 9

SP - 391

EP - 401

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 7

ER -